One of the three Pharmaceutical companies charged by the Food and Drugs Authority for importing fake drugs has dismissed the claims. Lymens Pharmaceuticals say the drugs sampled by the FDA were not taken directly from their warehouse. An official of the company, Jerry Sosu told Joy News’ Evans Mensah the deterioration of the drugs may be due to poor storage facilities at the various hospitals and pharmacy shops and not because Lymens imported a fake drug. His rebuttal follows a release by the FDA which indicted three companies, including, Sarkuff Pharmacy and Osons Chemists for importing “dangerous drugs” into the country. Oxytocin, a drug used to control the bleeding of women was one of the fake and contaminated drugs cited by the FDA to have been imported by the Pharmaceutical companies. One Dr Abdella of the Winneba Government Hospital who spoke to Joy News narrated how a young pregnant woman died after she was injected by the Oxytocin drug. National Security has begun investigations into the importation of fake and substandard medicines into the country. But Lymens Pharmaceuticals say they are not to blame for the deterioration of the drugs. Jerry Sosu said the FDA has not provided them with the analytical report to show that the drugs said to be contaminated were those that were sold out by Lymens. It may well be that the medicine were potent at the time it left the warehouse of Lymens but deteriorated due to poor storage at the various hospitals, Sosu said, adding for a drug to be potent, it has to be stored between 2-8 degrees celsius. He also dismissed the FDA allegations that their drugs were imported from “ghost companies.” According to him, their drugs were purchased from a broker in China whose name he would not mention. He admitted though that there were some “regulatory irregularity” during the importation of the drugs and they are in talks with the FDA to resolve that. He would not however disclose what those irregularities were. He said the company has recalled all the medicines said to have been contaminated to conduct their own tests. Thomas Amedzro Head of Post Market Surveillance at the FDA said they uncovered the fraud after a thorough surveillance at various pharmacies, hospitals etc. He dismissed the claims by the official from Lymens that the drugs were contaminated due to poor storage facilities. Amedzro challenged Lymens to provide their baseline sample which proved that the drugs were in good condition before they were distributed.